Iqirvo

Elafibranor, the active ingredient in Iqirvo, is a dual PPAR‑α/δ agonist presented as an oral tablet for oral use. It is being studied for its potential to improve liver inflammation and metabolic parameters in patients with non‑alcoholic steatohepatitis and related metabolic disorders.

GNH USA supplies Iqirvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iqirvo targets metabolic liver disease pathways, particularly those involved in non‑alcoholic steatohepatitis (NASH) and related conditions. - Non‑alcoholic steatohepatitis (NASH): may help reduce hepatic inflammation and fibrosis. - Dyslipidaemia: may improve serum lipid concentrations. - Metabolic syndrome: may influence insulin sensitivity and glucose metabolism.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Abdominal pain: mild discomfort in the upper abdomen. - Diarrhoea: loose stools occurring intermittently. - Increased serum creatinine: mild elevation observed in some patients.

Serious or Rare Side Effects: - Elevated liver enzymes: significant rise in ALT/AST levels. - Gallbladder disease: occurrence of cholelithiasis or cholecystitis. - Pancreatitis: acute inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Cardiovascular events: rare cases of myocardial infarction reported.

Before initiating therapy, consider patient history and concurrent conditions. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Renal function assessment: evaluate serum creatinine and eGFR. - Concomitant lipid‑lowering therapy: adjust doses if needed. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Elafibranor may interact with several drug classes; careful review is advised. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase elafibranor exposure. - High‑dose statins: risk of myopathy may be heightened. - Anticoagulants: potential for increased bleeding risk. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors: monitor for adverse effects. - Antidiabetic agents: possible enhancement of glucose‑lowering effect. - Bile‑acid sequestrants: may reduce absorption of elafibranor.